Want to see AU:WNX full AI Analyst Report?
Top Page
Wellnex Life Ltd
(Sydney:WNX)
Select Model
Select Model
Rating:47Neutral
Price Target:
AU$0.07
▼(-27.78% Downside)
Action:Reiterated
Date:09/06/26
The score is held down primarily by weak financial quality—continued losses, sharply lower FY2026 gross margin, and persistently negative operating/free cash flow, alongside increased leverage. Technicals are moderately supportive (above key shorter-term averages with neutral RSI and positive MACD), but valuation remains constrained by negative earnings and no stated dividend yield.
Positive Factors
Revenue rebound
Revenue has increased materially across the last two reported years, indicating improving scale and stronger demand for the company’s consumer healthcare offering. Continued top-line expansion can support greater operating leverage and provide a broader base from which to improve profitability over the next several quarters.
Negative Factors
Weak and declining gross margin
The sharp gross-margin deterioration indicates that revenue growth is not currently translating into comparable economic value. Persistently low or volatile margins would constrain funds available for marketing, product development, and distribution, making durable profitability harder to achieve.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue rebound
Revenue has increased materially across the last two reported years, indicating improving scale and stronger demand for the company’s consumer healthcare offering. Continued top-line expansion can support greater operating leverage and provide a broader base from which to improve profitability over the next several quarters.
Read all positive factors
Wellnex Life Ltd (WNX) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$4.82M
Dividend YieldN/A
Average Volume (3M)68.43K
Price to Earnings (P/E)―
Beta (1Y)2.55
Revenue Growth5.13%
EPS Growth87.49%
CountryAU
Employees3
SectorConsumer Defensive
Sector Strength42
IndustryPackaged Foods
Share Statistics
EPS (TTM)-0.06
Shares Outstanding73,026,810
10 Day Avg. Volume33,109
30 Day Avg. Volume68,431
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.20
Price to Sales (P/S)0.06
P/FCF Ratio-0.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.05
Revenue Forecast (FY)AU$48.60M
Wellnex Life Ltd Business Overview & Revenue Model
Company Description
Wellnex Life Limited, together with its subsidiaries, develops, markets, and sells health and wellness products in Australia, New Zealand, and the United Kingdom. The company offers topical anti-inflammatory creams, sprays, and roll-ons under the ...
How the Company Makes Money
Wellnex Life Ltd primarily makes money by generating revenue from the sale of consumer healthcare/OTC products under its owned or managed brands through pharmacy, retail, and other distribution channels. Key revenue streams typically include (1) w...
Wellnex Life Ltd Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
40
Negative
Cash Flow
24
Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 24.84M | 23.63M | 16.93M | 27.89M | 18.61M |
| Gross Profit | 2.78M | 6.88M | -776.00K | 4.75M | 4.50M |
| EBITDA | -815.00K | -6.62M | -10.57M | -6.82M | -6.35M |
| Net Income | -4.55M | -15.60M | -13.74M | -13.85M | -7.45M |
Balance Sheet | |||||
| Total Assets | 23.78M | 27.84M | 30.92M | 15.04M | 19.61M |
| Cash, Cash Equivalents and Short-Term Investments | 862.00K | 497.00K | 903.00K | 322.00K | 3.18M |
| Total Debt | 9.68M | 5.45M | 10.67M | 6.95M | 7.86M |
| Total Liabilities | 16.33M | 16.59M | 24.86M | 14.45M | 15.25M |
| Stockholders Equity | 7.45M | 11.25M | 6.06M | 594.00K | 4.36M |
Cash Flow | |||||
| Free Cash Flow | -2.81M | -666.00K | -6.82M | -6.19M | -8.65M |
| Operating Cash Flow | -2.81M | -666.00K | -6.82M | -6.19M | -8.61M |
| Investing Cash Flow | 10.00K | -8.29M | -13.42M | -2.20M | -3.65M |
| Financing Cash Flow | 3.17M | 8.55M | 20.82M | 5.53M | 7.66M |
Wellnex Life Ltd Technical Analysis
Negative
0.09
Price Trends
0.08
Negative
0.07
Negative
0.08
Negative
Market Momentum
>-0.01
Positive
29.57
Positive
<0.01
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:WNX, the sentiment is Negative. The current price of 0.09 is above the 20-day moving average (MA) of 0.07, above the 50-day MA of 0.08, and above the 200-day MA of 0.08, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 29.57 is Positive, neither overbought nor oversold. The STOCH value of <0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:WNX.
Wellnex Life Ltd Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
47 Neutral | AU$4.82M | -1.04 | -52.00% | ― | 5.13% | 87.49% | |
46 Neutral | AU$12.55M | -1.68 | -88.51% | ― | 11.96% | -81.99% | |
45 Neutral | AU$69.82M | -15.00 | -11.08% | ― | 9.08% | -183.87% | |
39 Underperform | AU$12.14M | -3.79 | 1795.70% | ― | 0.72% | -486.96% | |
39 Underperform | AU$18.32M | -0.01 | -130.72% | ― | -33.05% | 94.22% |
* Consumer Defensive Sector Average
AU:WNX
Wellnex Life Ltd
0.07
-0.13
-66.15%
AU:BUB
Bubs Australia Ltd.
0.08
-0.08
-51.25%
AU:NUC
Nuchev Pty Ltd
0.08
-0.06
-42.86%
AU:HCT
Holista Colltech Limited
0.03
-0.05
-57.69%
AU:NGS
Nutritional Growth Solutions Ltd.
0.02
>-0.01
-5.00%
Wellnex Life Ltd Corporate Events
Wellnex Life exits Pain Away, clears debt and refocuses on consumer health growth
Oct 29, 2026
Wellnex Life has completed the divestment of its Pain Away business and used the proceeds to repay $11.79 million in borrowings, leaving the company debt-free with $5.09 million in cash at 30 September 2026. The quarter also reflected transitional...
Wellnex Life Sets 2025 AGM, Details Proxy and Shareholder Question Process
Oct 29, 2026
Wellnex Life Limited has called its 2025 Annual General Meeting for 30 November 2026 in Melbourne, providing shareholders with details on how to attend in person or participate via proxy. Shareholders are invited to submit written questions for th...
Wellnex Life Shareholder Ceases Substantial Holding After Off‑Market Sale
Oct 5, 2026
A substantial shareholder in Wellnex Life Limited, JYSF Management Pty Ltd and Kirby Superannuation Pty Ltd on behalf of Jeffrey Yeh and Sze En Feng, has ceased to be a substantial holder in the company. The change follows an off‑market sale...
Wellnex Life Director Jeffrey Yeh Cuts Indirect Shareholding in Off-Market Trade
Oct 5, 2026
Wellnex Life has disclosed a significant change in the indirect shareholdings of director Jeffrey Yeh, in line with ASX reporting rules. Yeh’s interests, held through Kirby Superannuation Pty Ltd and JYSF Management Pty Ltd, have been substa...
Wellnex Life Completes Sale of Pain Away Business to Mentholatum
Sep 11, 2026
Wellnex Life Limited has completed the sale of its Pain Away business and associated assets to Mentholatum Australasia Pty Ltd, with all conditions precedent satisfied and the upfront purchase price settled following shareholder approval. The comp...
Wellnex Life shareholders back sale of Pain Away business
Sep 8, 2026
Wellnex Life Limited has announced that shareholders overwhelmingly approved the disposal of its Pain Away business at an Extraordinary General Meeting held on 8 September 2026. The resolution to divest Pain Away passed by poll with more than 99% ...
Wellnex Life appoints new part-time CFO as it advances post-divestment strategy
Aug 31, 2026
Wellnex Life Limited has announced a leadership change in its finance function, with Chief Financial Officer Vivienne Zhang stepping down and Chartered Accountant Joe Rinarelli taking on the CFO role on a part-time basis from 1 September 2026. Zha...
Wellnex Life Slashes FY26 Loss and Moves to Sell Pain Away Unit
Aug 31, 2026
Wellnex Life reported a marked turnaround in its FY26 audited results, with revenue up 5.1% to A$24.8 million and gross margin improving to 30.2%, while net loss shrank by 70.8% to A$4.5 million and EBITDA loss fell to A$1.7 million. Management at...
Wellnex Life Narrows Loss as Branded Revenue Grows Amid Going-Concern Warning
Aug 31, 2026
Wellnex Life reported a 5.1% rise in revenue to $24.8 million for the year ended 30 June 2026, driven mainly by its owned brands. Margins edged up to 30.2%, or $7.5 million, indicating improved profitability from core operations.The company cut it...
Wellnex Life Turns Cash Flow Positive as Revenue and Cost Discipline Drive FY26 Turnaround
Jul 31, 2026
Wellnex Life has reported its second consecutive quarter of positive net operating cash flow, marking a sharp turnaround in FY26 driven by rising customer receipts and tighter cost control. Receipts reached $5.7 million for the June quarter and $2...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.